Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01477034 · ClinicalTrials.gov registry record · NA

Vitamin D and Adipose Tissue Inflammation

A NA study of Obesity and Type 2 Diabetes Mellitus, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT01477034 is a NA study of Obesity and Type 2 Diabetes Mellitus that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 18 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01477034, a NA study of Obesity and Type 2 Diabetes Mellitus, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

Chronic, low-grade adipose tissue inflammation is a major risk factor for type 2 diabetes mellitus. The cause of adipose tissue inflammation has remained largely unclear. We hypothesize that vitamin D deficiency predisposes individuals to the development of adipose tissue inflammation, and that treatment of vitamin D deficient subjects with high dose vitamin D will reduce adipose tissue inflammation.

Interventions

  • DIETARY_SUPPLEMENT Vitamin D3

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2011-11
Est. Completion 2013-06
Phase NA

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT01477034

The ClinicalTrials.gov registry entry for NCT01477034 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Vitamin D3 is the first listed.

NCT01477034 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT01477034 about?

NCT01477034 is a clinical study titled "Vitamin D and Adipose Tissue Inflammation". Chronic, low-grade adipose tissue inflammation is a major risk factor for type 2 diabetes mellitus. The cause of adipose tissue inflammation has remained largely unclear. We hypothesize that vitamin D deficiency predisposes individuals to the development of adipose tissue inflammation, and that trea...

What is the current status of trial NCT01477034?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2011-11. Estimated completion is 2013-06.

What conditions does trial NCT01477034 study?

This clinical trial studies the following conditions: Obesity, Type 2 Diabetes Mellitus, Vitamin D Deficiency, Intestinal Permeability.

What interventions are being tested in trial NCT01477034?

The interventions under investigation include: Vitamin D3 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01477034?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01477034 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.